Pharma News

NEWS: Intercell vaccine patch fails Phase II clinical trial

Intercell's investigational vaccine enhancement patch system for avian H5N1 influenza has failed a Phase II study. The company is working under a contract with Human and Health services (HHS) to develop a dose-sparing approach with potential for a single dose immunization combining a H5N1 vaccine with Intercell's LT adjuvant patch.

New standard care of Advanced Melanoma presented in ASCO 2010 annual meeting

June 6, 2010 (Chicago, Illinois) — An experimental therapy for advanced melanoma has been shown to improve overall survival in patients, and is "on the road" to becoming the "new standard of care," said one of its investigators here at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting.

ICMR to launch task force projects on burden of rotavirus diarrhoea in India

Aiming to understand the potential health benefits of rotavirus vaccination and also to develop a national representative data on rotavirus burden and strains in India, the Indian Council of Medical Research (ICMR) will soon embark on task force projects on burden of rotavirus diarrhoea in India under the Indian Rotavirus Surveillance Network.

US FDA to review once-weekly treatment for type 2 diabetes Bydureon in October

Amylin Pharmaceuticals, Inc, Eli Lilly and Company and Alkermes, Inc announced that the US Food and Drug Administration (FDA) has classified the Bydureon (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

Pages